Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Too Old to Operate4d
Higher Magnesium Depletion Score Linked to Hyperuricemia Risk
The following is a summary of “Association between magnesium depletion score and prevalence of hyperuricemia in American ...
Too Old to Operate5d
Magnesium Depletion as a Risk Factor for Hyperuricemia in Adults
The following is a summary of “Association between magnesium depletion score and prevalence of hyperuricemia in American adults: a study based on NHANES 2007-2018,” published in the February 2025 ...
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...
TMJ42d
City of Milwaukee Health Department releases lead assessment report for Kagel Elementary
The City of Milwaukee Health Department has released more information on lead contamination at Kagel Elementary School, and ordered that all violations be addressed by March 11.
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises
Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also ...